Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer.

PURPOSE Several tumor markers have recently been applied for prostate cancer screening. We analyze the effectiveness of prostate specific antigen (PSA), age specific PSA, PSA velocity, volume adjusted PSA densities, change in PSA level following antibacterial therapy, free-to-total PSA ratio, alpha1-antichymotrypsin bound PSA, alpha2-macroglobulin bound PSA, alpha1-protease inhibitor bound PSA and human glandular kallikrein 2 in detecting prostate cancer. MATERIALS AND METHODS We conducted a review of the literature between September 2000 and February 2001. A total of 7,250 abstracts and articles published during the previous 12 years were retrieved from MEDLINE using the key words PSA and human glandular kallikrein 2. Of these reports 135 are included in this review. RESULTS We analyzed and systematized data from studies regarding the effectiveness of PSA and human glandular kallikrein 2 and their derivatives in the detection of prostate cancer. CONCLUSIONS Improvement in the specificity and sensitivity of PSA is imperative. Free-to-total PSA ratio, transition zone PSA density and change in PSA level increase the specificity of PSA to some extent. Protocols investigating the effectiveness of different combinations of these 3 measurements seem necessary for improving the effectiveness of prostate cancer screening among men within the diagnostic "gray zone." PSA velocity, age adjusted PSA levels and PSA density might be used in limited cases. alpha1-Antichymotrypsin, alpha2-macroglobulin and alpha1-protease inhibitor bound PSA, and human glandular kallikrein 2 are promising experimental methods.

[1]  J. Oesterling,et al.  Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. , 1995, The Journal of urology.

[2]  C. Powell,et al.  Prostate specific antigen--a screening test for prostatic cancer? , 1989, British journal of urology.

[3]  A. Pantuck,et al.  Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. , 1992, The Journal of urology.

[4]  H. Yamanaka,et al.  Determination of reference values for total PSA, F/T and PSAD according to prostatic volume in japanese prostate cancer patients with slightly elevated serum PSA levels. , 1999, Japanese journal of clinical oncology.

[5]  M. Solomon,et al.  Age specific prostate specific antigen reference ranges: population specific. , 1998, The Journal of urology.

[6]  T. Lindahl,et al.  Age-specific reference values for serum prostate-specific antigen in a community-based population of healthy Swedish men. , 1997, Scandinavian journal of clinical and laboratory investigation.

[7]  E. Metter,et al.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.

[8]  Y. Arai,et al.  Complexed prostate-specific antigen and its volume indexes in the detection of prostate cancer. , 1999, Urology.

[9]  J. Goméz,et al.  Serum prostate specific antigen as pre-screening test for prostate cancer. , 1992, The Journal of urology.

[10]  D. Chan,et al.  Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. , 1992, Cancer research.

[11]  C. Amling,et al.  Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. , 2000, The Journal of urology.

[12]  F. España,et al.  Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples. , 1998, Journal of Urology.

[13]  R. Babaian,et al.  Role of PSA and its indices in determining the need for repeat prostate biopsies. , 1997, Urology.

[14]  J. Breul,et al.  Value of Free Prostate-Specific Antigen (Hybritech Tandem-R) in Symptomatic Patients Consulting the Urologist , 2000, Urologia Internationalis.

[15]  H. D. de Koning,et al.  Prostate cancer detection at low prostate specific antigen. , 2000, The Journal of urology.

[16]  J. Hugosson,et al.  Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. , 2000, Urology.

[17]  J. Oesterling,et al.  Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis. , 1996, The Journal of urology.

[18]  F. Schröder,et al.  Screening, early detection, and treatment of prostate cancer: a European view. , 1995, Urology.

[19]  J. Oesterling,et al.  Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen. , 1997, The Urologic clinics of North America.

[20]  J. Morote,et al.  Effect of Inflammation and Benign Prostatic Enlargement on Total and Percent Free Serum Prostatic Specific Antigen , 2000, European Urology.

[21]  R. Vessella,et al.  Screening for prostatic carcinoma with prostate specific antigen. , 1992, The Journal of urology.

[22]  E. Higashihara,et al.  Comparisons of the Various Combinations of Free, Complexed, and Total Prostate–Specific Antigen for the Detection of Prostate Cancer , 2000, European Urology.

[23]  B. G. Blijenberg,et al.  The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. , 1995, Urology.

[24]  W. Catalona,et al.  Longitudinal screening for prostate cancer with prostate-specific antigen. , 1996, JAMA.

[25]  J. Anderson,et al.  Age-specific reference ranges for serum prostate-specific antigen. , 1995, Urology.

[26]  P. Bretton,et al.  Prostate-Specific Antigen and Digital Rectal Examination in Screening for Prostate Cancer: A Community-Based Study , 1994, Southern medical journal.

[27]  M. Luján,et al.  Prostate specific antigen variation in patients without clinically evident prostate cancer. , 1999, The Journal of urology.

[28]  D. Schmid,et al.  Free/total prostate-specific antigen ratio can prevent unnecessary prostate biopsies. , 1998, Urology.

[29]  T. Piironen,et al.  In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. , 1998, Urology.

[30]  M. Nomi,et al.  Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations , 1997, Cancer.

[31]  D. Chan,et al.  Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays. , 2000, Urology.

[32]  M. Stampfer,et al.  A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.

[33]  D. Ornstein,et al.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. , 1997, JAMA.

[34]  Y. Arai,et al.  Prostate specific antigen adjusted for the transition zone volume as an indicator of prostate cancer. , 1997, The Journal of urology.

[35]  J. Richie,et al.  Derivation and application of upper limits for prostate specific antigen in men aged 50-74 years with no clinical evidence of prostatic carcinoma. , 1995, British journal of urology.

[36]  M. Miller,et al.  Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations. , 1999, Urology.

[37]  W. Cooner,et al.  Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. , 1990, The Journal of urology.

[38]  P. Humphrey,et al.  Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. , 1995, The Journal of urology.

[39]  H. Klocker,et al.  Prostate cancer screening in Tyrol, Austria: experience and results. , 2000, European urology.

[40]  F. España,et al.  Prostate–Specific Antigen Complexed to α1–Antichymotrypsin in the Early Detection of Prostate Cancer , 2000, European Urology.

[41]  J. Oesterling,et al.  Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part II: Early detection strategies. , 1995, Urology.

[42]  B. Morris,et al.  Primary structure of a human glandular kallikrein gene. , 1987, DNA.

[43]  H. Lilja,et al.  Prostate specific antigen predominantly forms a complex with alpha1‐antichymotrypsin in blood. Implications for procedures to measure prostate specific antigen in serum , 1992, Cancer.

[44]  D. Deperthes,et al.  Short Communication Immunohistochemical Study Suggesting a Complementary Role of Kallikreins hK2 and hK3 (Prostate-Specific Antigen) in the Functional Analysis of Human Prostate Tumors , 2007 .

[45]  A. Zlotta,et al.  Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. , 1997, The Journal of urology.

[46]  W. Ellis,et al.  Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. , 1994, The Journal of urology.

[47]  U. Stenman,et al.  Prostate-specific antigen, clinical use and staging: an overview. , 1997, British journal of urology.

[48]  H. Lilja,et al.  Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. , 1990, European journal of biochemistry.

[49]  U. Stenman,et al.  Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin. , 1998, Clinical chemistry.

[50]  E. Metter,et al.  Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. , 1995, Urology.

[51]  D. Chan,et al.  Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. , 2000, The Journal of urology.

[52]  J. Moul,et al.  Age-specific reference ranges for serum prostate-specific antigen in black men. , 1996, The New England journal of medicine.

[53]  J. Richie,et al.  Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. , 2000, Urology.

[54]  E. Anderson.  Hudson et al. , 1977 .

[55]  J. Oesterling,et al.  The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older. , 1995, The Journal of urology.

[56]  W. Cooner,et al.  Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. , 1994, Urology.

[57]  J. Oesterling,et al.  Influence of patient age on the serum PSA concentration. An important clinical observation. , 1993, The Urologic clinics of North America.

[58]  M. Plebani,et al.  Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when? , 2000, Urology.

[59]  H. Lilja,et al.  Production of recombinant PSA and HK2 and analysis of their immunologic cross-reactivity. , 1995, Biochemical and biophysical research communications.

[60]  W. Catalona,et al.  Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. , 1994, The Journal of urology.

[61]  J. Oesterling,et al.  Prostate specific antigen: a decade of discovery--what we have learned and where we are going. , 1999, The Journal of urology.

[62]  H. Lilja,et al.  Three predominant proteins secreted by the human prostate gland , 1988, The Prostate.

[63]  J. Oesterling,et al.  Age-specific reference ranges for serum prostate-specific antigen. , 1995, The Canadian journal of urology.

[64]  P. Knekt,et al.  Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer , 1994, The Lancet.

[65]  E. Kikuchi,et al.  Prostate specific antigen adjusted for transition zone volume , 2000, Cancer.

[66]  W. Fair,et al.  Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. , 1997, The Journal of urology.

[67]  H. Carter,et al.  Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. , 1997, The Urologic clinics of North America.

[68]  W. Ellis,et al.  Transition zone prostate specific antigen density: lack of use in prediction of prostatic carcinoma. , 1998, The Journal of urology.

[69]  W. Catalona,et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.

[70]  E. Crawford,et al.  Efficiency of prostate‐specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age‐specific reference range as a cutoff for abnormal values , 1999, The Prostate.

[71]  C C Schulman,et al.  Prostate specific antigen density of the transition zone for early detection of prostate cancer. , 1998, The Journal of urology.

[72]  H. Lilja,et al.  Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. , 1994, European journal of biochemistry.

[73]  S. Egawa,et al.  Significance of free to total PSA ratio in men with slightly elevated serum PSA levels: a cooperative study. , 1998, Japanese journal of clinical oncology.

[74]  Downey,et al.  Asymptomatic inflammation and/or infection in benign prostatic hyperplasia , 1999, BJU international.

[75]  W. J. Allard,et al.  Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. , 1998, Clinical chemistry.

[76]  K. Kamoi,et al.  Correlation of histological inflammation in needle biopsy specimens with serum prostate- specific antigen levels in men with negative biopsy for prostate cancer. , 2000, Urology.

[77]  Serum prostate-specific antigen levels (PSA) in men without clinical evidence of prostate cancer: age-specific reference ranges for total PSA, free PSA, and percent free PSA. , 1999, Urology.

[78]  A. Semjonow,et al.  The clinical impact of different assays for prostate specific antigen , 2000, BJU international.

[79]  M. Brawer.  Screening for prostate cancer. , 2000, Seminars in surgical oncology.

[80]  S. Bigler,et al.  Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer. , 2000, The Journal of urology.

[81]  G. Murphy,et al.  A prostate antigen in sera of prostatic cancer patients. , 1980, Cancer research.

[82]  S. Loening,et al.  Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA. , 1999, Urology.

[83]  T. Horn,et al.  Prostatic specific antigen and benign prostatic hyperplasia. , 1996, Scandinavian journal of urology and nephrology.

[84]  U. Stenman,et al.  Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum. , 1999, Clinical chemistry.

[85]  G. Karazanashvili,et al.  Prostate–Specific Antigen (PSA) Value Change after Antibacterial Therapy of Prostate Inflammation, as a Diagnostic Method for Prostate Cancer Screening in Cases of PSA Value within 4–10 ng/ml and Nonsuspicious Results of Digital Rectal Examination , 2001, European Urology.

[86]  K Ito,et al.  Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer. , 2000, Urology.

[87]  J. Oesterling,et al.  Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. , 1996, Urology.

[88]  R. Joseph Babaian,et al.  The role of prostate‐specific antigen as part of the diagnostic triad and as a guide when to perform a biopsy , 1991, Cancer.

[89]  J. Morote,et al.  Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml. , 1997, The Journal of urology.

[90]  H. Klocker,et al.  Prostate carcinoma screening in the county of Tyrol, Austria , 1997, Cancer.

[91]  H. Lilja,et al.  Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. , 1996, Clinical chemistry.

[92]  K. Peters,et al.  Potential effects of age-specific reference ranges for serum prostate-specific antigen. , 1995, European urology.

[93]  C. Pilarsky,et al.  Diagnostic Significance of Prostate-Specific Antigen Velocity at Intermediate PSA Serum Levels in Relation to the Standard Deviation of Different Test Systems , 1998, Urologia internationalis.

[94]  D. Tindall,et al.  Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. , 1999, Urology.

[95]  D. Chan,et al.  Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. , 1999, Urology.

[96]  W. Catalona.  Re: Serum Prostate Specific Antigen as Pre-Screening Test for Prostate Cancer, by F. Labrie, A. Dupont, R. Suburu, L. Cusan, M. Tremblay, J.-L. Gomez and J. Emond, J. Urol., 147: 846–852, 1992 , 1993 .

[97]  C C Schulman,et al.  PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. , 1999, Urology.

[98]  C C Schulman,et al.  Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. , 2000, The Journal of urology.

[99]  O. Nilsson,et al.  Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. , 1991, Clinical chemistry.

[100]  The impact of prostate-specific antigen density in predicting prostate cancer when serum prostate-specific antigen levels are less than 10 ng/ml. , 1996, European urology.

[101]  B. Dalkin,et al.  Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. , 1993, The Journal of urology.

[102]  T. Reckwitz,et al.  The use of percent free PSA for early detection of prostate cancer. , 1999, Journal of andrology.

[103]  M K Brawer.  Prostate-specific antigen. , 2000, Seminars in surgical oncology.

[104]  T. Stamey,et al.  Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .

[105]  J. Pannek,et al.  Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer , 1998, Prostate Cancer and Prostatic Diseases.

[106]  M. Brawer,et al.  Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma. , 1998, The Journal of urology.

[107]  D. Tindall,et al.  Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. , 1999, Urology.

[108]  S. Loening,et al.  The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men. , 1998, British journal of urology.

[109]  O. Nilsson,et al.  Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. , 1993, The Journal of urology.

[110]  K. Pettersson,et al.  The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma , 1998, Cancer.

[111]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[112]  J. Goujon,et al.  Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. , 1997, The Journal of urology.

[113]  D. L. Dalton.  Elevated serum prostate-specific antigen due to acute bacterial prostatitis. , 1989, Urology.

[114]  U. Stenman,et al.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. , 1991, Cancer research.

[115]  H. Lilja.  A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. , 1985, The Journal of clinical investigation.

[116]  G. Murphy,et al.  Use of human prostate-specific antigen in monitoring prostate cancer. , 1981, Cancer research.

[117]  J Drago,et al.  The American cancer society national prostate cancer detection project. Findings on the detection of early prostate cancer in 2425 men , 1991, Cancer.

[118]  H. Lilja,et al.  Impaired secretory function of the prostate in men with oligo-asthenozoospermia. , 1995, Journal of andrology.

[119]  H. Lilja,et al.  Prostate-specific antigen: molecular forms and the human kallikrein gene family. , 1997, British journal of urology.

[120]  E. van Marck,et al.  Inflammation in Prostate Biopsies of Men without Prostatic Malignancy or Clinical Prostatitis , 2000, European Urology.

[121]  E. Higashihara,et al.  Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL. , 2000, Urology.

[122]  J. Oesterling,et al.  Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: Estimating the risks and benefits of an early detection program. , 1995, Urology.

[123]  Y. Asada,et al.  Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia , 1994, The Prostate.

[124]  T. Stamey,et al.  Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate. , 1995, The Journal of urology.

[125]  K. Miyake,et al.  Prostate-specific antigen levels in acute and chronic bacterial prostatitis. , 1993, Hinyokika kiyo. Acta urologica Japonica.

[126]  P. Vihko.  Prostate-Specific Antigen and Human Glandular Kallikrein , 1995 .

[127]  U. Stenman,et al.  Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer. , 2000, Urology.